CGT4859

· Cogent Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CGT4859, covering 2026-04-17 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors [Phase 1, Phase 2]

See pricing